IRD · Company research
Opus Genetics, Inc. Common Stock (IRD): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
24records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) Stock Price, News, Quote & History - Yahoo! Finance Canada | Opus Genetics, Inc. (IRD) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| IRD Oct 2026 2.500 call (IRD261016C00002500) interactive stock chart - Yahoo Finance UK | IRD Oct 2026 2.500 call (IRD261016C00002500) interactive stock chart Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 16, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Oct 16, 2026 | neutral | 0 | 0.6 |
| IRD Oct 2026 2.500 call (IRD261016C00002500) stock price, news, quote and history - Yahoo Finance UK | IRD Oct 2026 2.500 call (IRD261016C00002500) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 16, 2026 | neutral | 0 | 0.6 |
| Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia | Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% (RYZUMVI®) for treating presbyopia in adults, expanding its previous indication for pharmacologically-induced mydriasis. The approval was supported by positive Phase 3 VEGA-2 and VEGA-3 trial results and will trigger a milestone payment from commercial partner Viatris Inc. Presbyopia affects approximately 90% of U.S. adults over 45, and the drug offers a non-invasive treatment option. | View source ↗ | GlobeNewswire Inc. | Oct 16, 2026 | bullish | 1 | 1 |
| Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia | Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% (RYZUMVI®) for treating presbyopia in adults, expanding its previous indication for pharmacologically-induced mydriasis. The approval was supported by positive Phase 3 VEGA-2 and VEGA-3 trial results and will trigger a milestone payment from commercial partner Viatris Inc. Presbyopia affects approximately 90% of U.S. adults over 45, and the drug offers a non-invasive treatment option. | View source ↗ | GlobeNewswire Inc. | Oct 16, 2026 | bullish | 1 | 1 |
| FDA approves an eye drop for age-related near-vision loss affecting about 90% of U.S. adults over 45 - Stock Titan | FDA approves an eye drop for age-related near-vision loss affecting about 90% of U.S. adults over 45 Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| IRD Oct 2026 10.000 put (IRD261016P00010000) interactive stock chart - Yahoo Finance UK | IRD Oct 2026 10.000 put (IRD261016P00010000) interactive stock chart Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 16, 2026 | neutral | 0 | 0.6 |
| With Phase 3 fully enrolled, Opus Genetics (IRD) expects to begin eye gene therapy dosing. - Stock Titan | With Phase 3 fully enrolled, Opus Genetics (IRD) expects to begin eye gene therapy dosing. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Adults in a gene therapy trial saw vision gains through 24 months. Children improved through six months. - Stock Titan | Adults in a gene therapy trial saw vision gains through 24 months. Children improved through six months. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| FDA Decision Watch: 3 Stocks With Potential October Catalysts As MRK Drops Out - Stocktwits | FDA Decision Watch: 3 Stocks With Potential October Catalysts As MRK Drops Out Stocktwits | View source ↗ | Stocktwits | Oct 5, 2026 | neutral | 0 | 0.6 |
| IRD Should I Buy - Intellectia AI | IRD Should I Buy Intellectia AI | View source ↗ | Intellectia AI | Oct 3, 2026 | neutral | 0 | 0.6 |
| A fund sells shares in Opus Genetics (IRD), leaving a 3.24M-share holding. - Stock Titan | A fund sells shares in Opus Genetics (IRD), leaving a 3.24M-share holding. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Small-cap stocks with strong momentum grades and triple-digit YTD gains (IRD:NASDAQ) - Seeking Alpha | Small-cap stocks with strong momentum grades and triple-digit YTD gains (IRD:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 17, 2026 | neutral | 0 | 0.6 |
| Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD) - Seeking Alpha | Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 10, 2026 | neutral | 0 | 0.6 |
| IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial - Yahoo Finance | IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial Yahoo Finance | View source ↗ | Yahoo Finance | Sep 9, 2026 | neutral | 0 | 0.6 |
| Why Opus Genetics (IRD) Stock Is Up Today - Quiver Quantitative | Why Opus Genetics (IRD) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 9, 2026 | neutral | 0 | 0.6 |
| Why Opus Genetics (IRD) Stock Is Up Today - Quiver Quantitative | Why Opus Genetics (IRD) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 9, 2026 | neutral | 0 | 0.6 |
| Opus Genetics Plans OPGx-BEST1 Data Webcast Sept. 9 | IRD Stock News - Stock Titan | Opus Genetics Plans OPGx-BEST1 Data Webcast Sept. 9 | IRD Stock News Stock Titan | View source ↗ | Stock Titan | Sep 2, 2026 | neutral | 0 | 0.6 |
| Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data - Yahoo Finance | Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data Yahoo Finance | View source ↗ | Yahoo Finance | Sep 1, 2026 | neutral | 0 | 0.6 |
| Citizens reiterates Opus Genetics stock rating on Viatris partnership potential - Investing.com | Citizens reiterates Opus Genetics stock rating on Viatris partnership potential Investing.com | View source ↗ | Investing.com | Aug 28, 2026 | neutral | 0 | 0.6 |
| Top 3 Health Care Stocks That May Rocket Higher In July - Benzinga | Top 3 Health Care Stocks That May Rocket Higher In July Benzinga | View source ↗ | Benzinga | Jul 20, 2026 | neutral | 0 | 0.6 |
| IRD Forecast — Price Target — Prediction for 2027 - TradingView | IRD Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Opus Genetics, Inc. Common Stock (IRD) Stock Price: Oct 15 Close $4.05 - Gotrade | Opus Genetics, Inc. Common Stock (IRD) Stock Price: Oct 15 Close $4.05 Gotrade | View source ↗ | Gotrade | Feb 5, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.